INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines. Carole Ho, M.D., will join Lilly as executive vice president and president, Lilly...Read more
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been appointed to Denali’s Board of Directors. Mr. Van Hauwermeiren is co-founder and Chief Executive Officer of argenx. Carole Ho, M.D., who has served as Denali’s Chief Medical Officer and Head of Development since 2015, will be...Read more
New leadership appointments strengthen Sight Sciences’ commitment to advancing our interventional dry eye initiatives and driving scalable operations and growth MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care,...Read more
Responsible for Corporate Development, Investor Relations, Government Affairs REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer. Mr. Sood’s responsibilities include key externally facing and strategic functions. “We are...Read more
RESEARCH TRIANGLE PARK, N.C. / Nov 05, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today. Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women’s Hospital in Boston and the Sidney Farber Professor of Medicine at the Dana-Farber Cancer...Read more
Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board of Directors has unanimously approved a leadership transition plan to become effective January 1,...Read more
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company’s Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience...Read more
Changes strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company’s ongoing development initiatives Matthew Davis, M.D., RPh will join immediately as Chief Development Officer Gary Slatko, M.D., M.B.A, will become interim Chief Medical Officer Peter Boyd, M.B.A, has been promoted to Chief People Officer WARREN, N.J., Nov. 04, 2025...Read more
SALT LAKE CITY, UT / ACCESS Newswire / November 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Kevin C. Timken, Esq to its Board of Directors. Mr. Timken, who served as UTMD's outside legal counsel for over twenty years prior to his retirement in 2025, graduated with a J.D. degree from the University of Utah College of Law in 1997. The Board believes his robust understanding of the...Read more
PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes. Effective November 1, 2025, Olivier te Boekhorst began...Read more
Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation PARSIPPANY, N.J. / Nov 03, 2025 / Business Wire / Zoetis Inc. (NYSE: ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal...Read more
IRVINE, Calif., Nov. 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, has appointed Michael Dennison, most recently Vice President of Sales, as President of North America. Dennison has held nearly every sales position in the aesthetic medical device industry, consistently producing at the highest level in each. With close to a decade of leadership experience at...Read more
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (CBO). Dr. Hawryluk will lead Prime’s corporate and business development initiatives, corporate strategy, and alliance management functions,...Read more
Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in 2025 HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary...Read more
MALVERN, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MALVERN, Pa., November 3, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of William (“Bill”) Plovanic, CFA, to its Board of Directors. Mr. Plovanic brings a distinctive combination of capital markets expertise and...Read more
Mark Quick Appointed Chief Financial Officer, Bringing Extensive Public Company Capital Markets Expertise Current CFO, Stefano Picone, will take on a Transitional Strategic Role to Support Leadership Continuity During Growth Phase Leadership additions follow submission of next-generation Novasight™ to the FDA for 510(k) clearance TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Conavi Medical (“Conavi” or the...Read more
WILMINGTON, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced that Chelsea Clinton, the longest-serving member of its Board of Directors, having joined the Board in early 2017, will conclude her service as of October 31, 2025. During her over eight years of dedicated service, Ms. Clinton played a pivotal role in guiding Clover’s evolution...Read more
King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of...Read more
Châtillon, France, October 30, 2025 - DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the...Read more
FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that Carsten Brunn, Ph.D., was named as Chairman of the Board of Directors, effective October 29, 2025. Dr. Brunn, who currently serves as the Company’s President and Chief Executive Officer and as a member of the Board, will...Read more
LONDON & NEW YORK / Oct 29, 2025 / Business Wire / Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective immediately. Dr. Jonas brings more than three decades of leadership in pharmaceutical research and development, with a particular focus on...Read more
CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered...Read more
Mr. Edick brings extensive industry experience across product development, commercial launch, and growth strategy SOUTH SAN FRANCISCO, Calif. / Oct 29, 2025 / Business Wire / Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Mr....Read more
Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board PARSIPPANY, N.J. / Oct 28, 2025 / Business Wire / Zoetis Inc. (NYSE: ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur...Read more
Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Ted W. Love, M.D., has been appointed to the Company's Board of Directors, effective December 1, 2025. Dr. Love brings more than 30 years of expertise in drug...Read more
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on advancing PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease, with Phase 2 IND submission planned for H1 2026 Carlsbad, CA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the...Read more
Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader...Read more
Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), today announced that its Board of Directors (the “Board”) has appointed director...Read more
Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the firm Appointment adds deep business strategy, transactional, and commercial expertise as CervoMed prepares for Phase 3 and commercialization planning BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company), a clinical-stage biotechnology company developing...Read more
SAN DIEGO / Oct 27, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a renowned researcher, entrepreneur, and clinician with extensive leadership experience at healthcare research institutions and private organizations. He currently serves as Chair of the Department of Medicine at...Read more
JERSEY CITY, N.J. / Oct 27, 2025 / Business Wire / Organon (NYSE: OGN) (“Organon” or “the company”) today announced that its Board of Directors has appointed the Company’s Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Morrissey in his new role....Read more
Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive Officer Derrick Sung, former Pulmonx Chief Financial Officer, appointed Chief Operating Officer and Chief Financial Officer Steve Williamson and Mehul Joshi have resigned from their respective roles at the Company, effective immediately Preliminary, unaudited third quarter 2025 revenue...Read more
ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei Melnik had taken over the responsibilities of CEO. Mr Sheridan has returned to the position of CEO effective immediately and will guide the company through the final 2025...Read more
Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership deals Her more than 30 years of experience include leadership roles in the UK and US, from early research through to product approval in cancer immunotherapy, making her the ideal candidate to lead the next stage of execution of Evaxion’s strategy Birgitte...Read more
Vancouver, Canada, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel neuroplastogens-derived therapeutics to solve major under-treated health problems, today announced the appointment of Mary-Elizabeth Gifford as Chief of Global Impact. In this role, Gifford will lead efforts to strengthen...Read more
Planned Leadership Transition Completed PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company’s Board of Directors. He...Read more
ACTON, Mass. / Oct 23, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert (“Robbie”) L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company’s board of directors, effective October 31, 2025. Mr. Huffines joins the board as an...Read more
SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Abraham (“Abe”) Bassan and Vasudev Bailey, Ph.D., to its Board of Directors. In conjunction with the new appointments, Andrew Farquharson and Maulik Nanavaty have stepped down from...Read more
Calgary, AB – October 23, 2025 - TheNewswire – Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF), (the “Company” or “Voyageur”) a Canadian developer of pharmaceutical-grade barium and iodine for medical imaging contrast media, is pleased to announce, subject to regulatory approval, the expansion of its board of directors and the appointment of two experienced Wall Street executives: Jeffrey J. Kraws, an award-winning Wall Street...Read more
SOUTH SAN FRANCISCO, Calif. / Oct 22, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the appointment of Suresh Gunasekaran to its Board of Directors. Suresh currently serves as President and Chief Executive Officer at UCSF Health, an...Read more
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and...Read more
Geoff McDonough, MD to step down as CEO & President and become Chair of the Company’s Board of Directors Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD...Read more
Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that...Read more
MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative’s global commercial operations and innovation. A seasoned executive with over...Read more
ST. PAUL, Minn., Oct. 21, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson. Ms. Knight brings over 30 years...Read more
SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (Nasdaq: CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of...Read more
RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the...Read more
RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the...Read more
WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the appointments of Adam Villa as Senior Vice President, Technical Operations, and Ashley Jones as Senior Vice President, People & Workforce Strategy. “We are thrilled to welcome Adam and...Read more
Leadership team addition to drive strategic long-term value creation and partnering strategy SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice President, Chief Business Officer. In this role, Ms. Lester will lead the Company’s strategy and business...Read more
CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately. "We are thrilled to welcome Dr. Gow to our executive team," said Vish Seshadri,...Read more
Industry Veteran Steve La Neve Named Chief Executive Officer Suzanne Winter to Retire as President and CEO Company Appoints Steven F. Mayer as Transformation Board Sponsor Chan W. Galbato Nominated to Board of Directors MADISON, Wis., Oct. 20, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced it is engaging in a significant organizational, strategic, and operational transformation. To accelerate this...Read more
Yasmine Wasfi, M.D., Ph.D., FCCP Promoted to CMO, Effective Immediately CMO Ray Pratt, M.D., FACP to Transition to Senior Medical Advisor LANGHORNE, Pa. / Oct 17, 2025 / Business Wire / Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced Yasmine Wasfi, M.D., Ph.D., FCCP has been promoted to CMO, effective immediately. She...Read more
WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to its Board of Directors, effective today. Ms. Dorton has more than 30 years of industry expertise and leadership in healthcare and life sciences including service on several boards of public life science companies, executive financial...Read more
Board Chairman Cary Vance appointed Interim CEO Board member Jan Stern Reed appointed Lead Independent Director Third quarter 2025 preliminary revenue expected to be approximately $17 million VALENCIA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced that the Board of Directors has named...Read more
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board of Directors, effective immediately. Mr. Bathery brings more than 30 years of experience in...Read more
Kelowna, British Columbia – October 16, 2025 – TheNewswire - Rize Oncology Inc. (the “Company”), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, today announced the resignation of Daren Graham as Executive Chairman and interim Chief Executive Officer of the Company. P. Gage Jull, a current Director of the Company, has been appointed the Company’s interim Chief Executive Officer....Read more
AUSTIN, Texas / Oct 15, 2025 / Business Wire / MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company today announced the appointment of industry veteran Thomas W. Lynch, Ph.D. as Chief Business Officer (CBO), effective October 20, 2025. “Tom’s combination of biotech depth and software commercialization expertise directly supports MindWalk’s next path of growth,” said Dr. Jennifer Bath CEO of...Read more
Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease research WESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Kent E. Kester, MD, FACP, FIDSA, FASTMH to...Read more
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in...Read more
ENGLEWOOD, Colo., Oct. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Bret Wise to its Board of Directors. Mr. Wise will also serve as Chair of the Audit Committee. "Bret Wise is a great addition to our Board of...Read more
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to...Read more
Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs WESTLAKE VILLAGE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (“Turn” or the “Company”), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, announces the appointment of Arthur Golden, a senior corporate board advisor with...Read more
NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice President of Regulatory Affairs. Throughout his career, Dr. Rawls has led or contributed to more than a dozen successful regulatory filings and product approvals in the United States, Europe, and Japan, with specific experience in neuropsychiatric...Read more
Appointment adds three decades of financial and operational leadership to Soleno’s Board REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member...Read more
Four new executives appointed, including new Chief Commercial Officer, to lead commercial strategy and operations FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced several executive transitions and appointments designed to align the company’s leadership structure with its...Read more
TAMPA, FLORIDA / ACCESS Newswire / October 13, 2025 / Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the re-appointment of Prashant Patel, RPh as President, Interim-CEO and Member of the Board of Directors. Mr. Patel had resigned from the positions of President & Member of the...Read more
Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, announced the appointment of Guido J. Neels to the Company’s Board of Directors. Mr. Neels will also serve as a member of the audit committee of the Board. In...Read more
Toronto, Ontario--(Newsfile Corp. - October 10, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the appointment of Michael Raimondo, a 30-year veteran in sales and operations in the healthcare industry to its Board of Directors. Michael was part of Therma's advisory Board,...Read more
BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital Markets, effective immediately. Mr. Kane brings 20 years of experience and a proven track record in investor relations, strategic...Read more
MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors, and the departure of Lisa Colleran, who has stepped down following five years of service on the Board. Dr. Rocchio is a...Read more
NEW YORK, NY, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announces the addition of Dr. Laura A. Philips to its board of directors as an independent director at closing of the merger with DiamiR Biosciences Corp. Dr. Philips is the co-founder, President, and Chief Executive Officer of...Read more
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. Neil Klompas, CPA, CA to its Board of Directors, effective immediately. Mr. Klompas brings over 30 years of experience...Read more
Brings decades of leadership in laboratory testing, clinical diagnostics, payor strategy, and sales growth Extensive track record in commercializing advanced laboratory testing and insurer strategies IRVINE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), a global provider of advanced diagnostic solutions, today announced the appointment of Gary Huff to its Board of Directors as an independent board member....Read more
WESTBROOK, Maine / Oct 07, 2025 / Business Wire / IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company's Board of Directors, effective October 6, 2025. "We are extremely pleased to welcome Karen to the IDEXX Board of Directors," said Lawrence D. Kingsley, the Company's Independent Non-Executive Board Chair. “Karen is a highly accomplished...Read more
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven leader with more than 20 years of commercial experience in the biopharmaceutical industry, will be responsible for developing and executing the sales and marketing strategy for Neurocrine's...Read more
Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced leadership changes at its wholly-owned subsidiary, ImprimisRx. Frank Mullery has been appointed as Chief Executive Officer and Bridseida Cruz...Read more
Leader with Long Track Record in Building World-Class Biopharma Companies and Driving Late-Stage Development and Commercial Execution Arthur Tzianabos Resumes Chairman of the Board Role BEDFORD, Mass. / Oct 06, 2025 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced that its Board of Directors...Read more
New VP Blaine Lindsey to Drive National Enterprise Growth; Gulf Region President Shannon Jacobs to Scale Operations in High-Need Markets SAN FRANCISCO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI‑powered physician‑enablement platform, today announced that Blaine...Read more
FRAMINGHAM, Mass. & SALISBURY, England / Oct 06, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. “I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY,” said Ben Palleiko, Chief Executive Officer of KalVista. “Their...Read more
LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its Board of Directors (BoD) and senior leadership, and other corporate updates. “The updates we announced today mark an important and timely step as we...Read more
NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the appointment of John Leaman, MD, to its board of directors as an independent director, effective October 1, 2025. In addition, Traws’ Board of...Read more
Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage biotech SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of...Read more
TruBridge is the platform of choice for rural and community healthcare - driven by a relentless focus on client success and execution at a time when providers need us most. MOBILE, Ala. / Oct 03, 2025 / Business Wire / TruBridge (NASDAQ: TBRG), a leading provider of revenue cycle management and healthcare technology solutions for rural and community healthcare organizations, today announced the appointment of Michael (Mike) Daughton as...Read more
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company. “Brian is joining our Board during a...Read more
Proven Executive Brings Extensive Experience in Senior Living, Healthcare, and Hospitality and Track Record of Driving Durable, Sustainable Operational Excellence NASHVILLE, Tenn., Oct. 2, 2025 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) ("Brookdale" or the "Company") today announced the appointment of Nick Stengle as Chief Executive Officer and as a member of the Brookdale Board of Directors, effective October 6, 2025....Read more
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice President, US Operations at Novo Nordisk A/S and President at Novo Nordisk Inc., has been appointed to the company’s Board of Directors. Mr. Moore brings a wealth of experience from his 27-year career in the industry, including broad...Read more
FRAMINGHAM, Mass. & SALISBURY, England / Oct 02, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit Committee of the Board. In connection with Ms. Sensenig’s appointment to the Audit Committee, Nancy Stuart will transition off the Audit Committee but...Read more
Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care Enablement As part of a planned transition Dr. Katarzyna Mazur-Hofsäß will retire by year end BAD HOMBURG, Germany, Oct. 1, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, has...Read more
WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. “We are...Read more
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE